Enquirer Consulting Group

Reachable Buyer Map

Prepared for Nabil Rahoma · Delta Pharmaceuticals · August 2026
Manufacturers in this market grow through three routes: the field force, the distributor relationship and the annual trade fair calendar. All three share one limit, which is that they reach whoever is already in the room. This map is the layer outside the room, across Egypt and the export markets around it. The commercial buyers a pharmaceutical manufacturer can be introduced to directly, who signs inside each group, and roughly how many there are.
Importers and licensed agents across the region
The largest reachable group on this page, and the one that decides whether a product ever reaches a shelf outside its home market. In most Gulf, Levant and African markets a local agent is a regulatory condition of registration rather than a commercial preference, so the partner is chosen before the demand exists.
Who signs: managing director or owner, business development director, portfolio or in-licensing manager, regulatory affairs head.
600 to 900
pharmaceutical importers, distributors and licensed agents across roughly twenty Gulf, Levant, North African and East African markets
Private hospitals and hospital groups
The buyer that orders on a formulary rather than a prescription, which makes the decision institutional and repeatable. Group operators matter far more than the raw hospital count, because one relationship carries several sites.
Who signs: hospital pharmacy director, procurement manager, medical director, and at group level the supply chain lead.
1,000 to 1,300
private hospitals in Egypt, alongside a much smaller number of multi-site groups that concentrate the buying
Contract manufacturing and in-licensing counterparties
Companies that need capacity, a dossier or a local manufacturing route, including brand owners with no plant of their own. Commercially the most interesting segment on this page, because the counterparty is often a company you also meet as a competitor.
Who signs: chief executive or managing director, business development and licensing lead, head of operations, supply chain director.
Roughly 130 to 170 in Egypt
licensed pharmaceutical manufacturing companies inside Egypt, with several hundred more across the wider region; a small, named audience rather than a volume one
The nutraceutical, supplement and cosmeceutical brand layer
The fastest moving group in the region and the one least served by traditional pharma selling. Brand owners here rarely own production, buy capacity and formulation together, and decide in weeks rather than quarters.
Who signs: founder or general manager, brand or category manager, head of product development, sourcing lead.
No single register
brand owners are licensed as traders rather than as producers in most markets, so they do not appear in any manufacturing register; identified one at a time, which is why the segment stays open
Wholesale and distribution inside Egypt
A concentrated layer where a handful of national operators carry most of the volume and a regional tail carries the rest. Access here is a relationship question rather than a reach question, which makes it the least useful segment to work at scale and the most useful to work by name.
Who signs: purchasing director, category or portfolio manager, branch general manager, commercial director.
A concentrated layer
national wholesalers hold most volume above a long regional tail; the layer is not published as a single register
Institutional, tender and donor funded buyers
Ministries, insurance funds, military and university hospitals, and the donor funded procurement that runs alongside them across Africa. Slow, formal, and unusually durable once a supplier is qualified.
Who signs: tender and procurement officers, formulary committee members, medical supply directors, and the technical evaluators who score the bid.
A named list, not a count
a small number of national buying bodies in each market, plus donor funded procurement channels; reached by named person rather than by volume

Where the openings are

1
There are two buyers here and they never meet. One is clinical and is reached by the field force, one prescriber at a time. The other is commercial, sits inside an importer, a licensing team or a brand, and is never visited by a representative at all. The second group is the one this map is about, and it is usually the one nobody owns internally.
2
Export growth is a partner problem before it is a demand problem. Each new market needs a registered local agent, and that search is normally done once a year, in person, at a fair. Finding and qualifying agents is a named-role job that runs perfectly well twelve months a year, and the market rarely treats it that way.
3
A trade fair reaches the companies that came. The counterparties most worth a conversation, the ones looking for capacity or a dossier this quarter, are frequently the ones that sent nobody. A channel built on named companies catches them. A calendar built on events cannot.
4
Capacity sells to the people you already compete with. Toll manufacturing, licensing and the supplement brand layer are all bought by a small, named list of executives, not by a market. Small lists are the cheapest thing in outbound to work properly, and they are almost always the last thing anyone gets to.
Built from public market data covering registered manufacturers, importers and health facilities across Egypt and the wider region, and counts are banded deliberately. Registers differ market by market in what they publish and how often they refresh, so these figures describe scale rather than a finished list. Brand owners who outsource production, and the donor funded channels, are described rather than counted because no public register holds them. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com